Evidence map›Paper›PMID 33143378›Full record

ArticleMicromachines2020

A Novel Microfluidic Method Utilizing a Hydrofoil Structure to Improve Circulating Tumor Cell Enrichment: Design and Analytical Validation.

Gürhan Özkayar, Ege Mutlu, Şebnem Şahin, Yağmur Demircan Demircan Yalçın, Taylan Töral, Haluk Külah, Ender Yıldırım, Özge Zorlu, Ebru Özgür

Open access · goldAbstract read
In one paragraph

Article in Micromachines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Gürhan ÖzkayarMikro Biyosistemler A.Ş., ODTÜ Teknokent MET Yerleskesi, No:280/B/10, 06530 Ankara, Turkey.
Ege MutluMikro Biyosistemler A.Ş., ODTÜ Teknokent MET Yerleskesi, No:280/B/10, 06530 Ankara, Turkey.
Şebnem ŞahinMikro Biyosistemler A.Ş., ODTÜ Teknokent MET Yerleskesi, No:280/B/10, 06530 Ankara, Turkey.
Yağmur Demircan Demircan YalçınMikro Biyosistemler A.Ş., ODTÜ Teknokent MET Yerleskesi, No:280/B/10, 06530 Ankara, Turkey.
Taylan TöralMikro Biyosistemler A.Ş., ODTÜ Teknokent MET Yerleskesi, No:280/B/10, 06530 Ankara, Turkey.
Haluk KülahMikro Biyosistemler A.Ş., ODTÜ Teknokent MET Yerleskesi, No:280/B/10, 06530 Ankara, Turkey.
Ender YıldırımMikro Biyosistemler A.Ş., ODTÜ Teknokent MET Yerleskesi, No:280/B/10, 06530 Ankara, Turkey.ORCID 0000-0002-7969-2243
Özge ZorluMikro Biyosistemler A.Ş., ODTÜ Teknokent MET Yerleskesi, No:280/B/10, 06530 Ankara, Turkey.ORCID 0000-0002-9570-0434
Ebru ÖzgürMikro Biyosistemler A.Ş., ODTÜ Teknokent MET Yerleskesi, No:280/B/10, 06530 Ankara, Turkey.
ODTÜ Teknokent (Turkey) · TRMiddle East Technical University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Being one of the major pillars of liquid biopsy, isolation and characterization of circulating tumor cells (CTCs) during cancer management provides critical information on the evolution of cancer and has great potential to increase the success of therapies. In this article, we define a novel strategy to effectively enrich CTCs from whole blood based on size, utilizing a spiral microfluidic channel embedded with a hydrofoil structure at the downstream of the spiral channel. The hydrofoil increases the distance between the streams of CTCs and peripheral blood cells, which are already distributed about two focal axes by the spiral channel, thereby improving the resolution of the separation. Analytical validation of the system has been carried out using Michigan Cancer Foundation-7 (MCF7) breast cancer cell lines spiked into blood samples from healthy donors, and the performance of the system in terms of white blood cell (WBC) depletion, CTC recovery rate and cell viability has been shown in single or two-step process: by passing the sample once or twice through the microfluidic chip. Single step process yielded high recovery (77.1%), viable (84.7%) CTCs. When the collected cell suspension is re-processed by the same chip, recovery decreases to 65.5%, while the WBC depletion increases to 88.3%, improving the purity. Cell viability of >80% was preserved after two-step process. The novel microfluidic chip is a good candidate for CTC isolation applications requiring high recovery rate and viability, including functional downstream analyses for variety of cancer types.

Indexed as

cancercirculating tumor cellsinertial particle focusingliquid biopsymicrofluidics

Identifiers

PMID33143378
PMCPMC7693848
OpenAlexW3097089541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.